Clinical Trial Update: A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of Glivec (imatinib) and Gemzar (gemcitabine) in unresectable, refractory malignant mesothelioma. The current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Gemzar (gemcitabine)
• Glivec (imatinib)

Snippet

Sponsor: Gruppo Italiano MEsotelioma | Conditions: Mesothelioma | Phase 2 | Status: UNKNOWN